Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest rheumatoid arthritis Stories

2013-10-30 08:32:29

The New Oral JAK Inhibitor Xeljanz Has Yet to Carve-Out a Distinct Place in the RA Treatment Algorithm, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists are moderately satisfied with the currently available biologic agents as well as Pfizer's Xeljanz for the treatment of...

2013-10-28 11:50:33

Research is among several Mayo studies being presented at American College of Rheumatology meeting CORRECTS second age group studied to 40 to 59 instead of 50 to 59. It may seem counterintuitive, but young and middle-aged fibromyalgia patients report worse symptoms and poorer quality of life than older patients, a Mayo Clinic study shows. Fibromyalgia most often strikes women. It is characterized by widespread musculoskeletal pain with fatigue, sleep, memory and mood issues. The...

2013-10-28 11:39:38

Early menopause is risk factor, research presented at American College of Rheumatology meeting shows People with rheumatoid arthritis and other chronic inflammatory conditions are at higher risk of heart disease. Who is in the most danger, why and how best to prevent and detect cardiovascular complications are important questions for physicians and researchers. Mayo Clinic studies presented at the American College of Rheumatology annual meeting shed new light on this connection, in part by...

2013-10-28 08:30:22

ALBUQUERQUE, N.M., Oct. 28, 2013 /PRNewswire/ -- Exagen Diagnostics, a leading medical diagnostic company focused in rheumatology, today announced the addition of Arthur Weinstein, M.D., MACR, FRCP, as its newest board member and adviser to Exagen's scientific team. (Logo: http://photos.prnewswire.com/prnh/20131028/LA05125LOGO) Dr. Weinstein is professor of medicine at Georgetown University Medical Center and Associate Chairman, Department of Medicine, and Director, Section of...

2013-10-28 08:29:30

Nearly 70 Percent of Patients Receiving SIMPONI ARIA at Two Years Demonstrated ACR 20 Response SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- New two-year results of a Phase 3 study sponsored by Janssen Research & Development, LLC (Janssen) showed that SIMPONI(®) ARIA(TM) (golimumab) for infusion in combination with methotrexate inhibited radiographic progression in patients with moderately to severely active rheumatoid arthritis (RA) at week 24, and continued to inhibit radiographic...

2013-10-28 08:29:21

Integrated Analysis of Two Pivotal Phase 3 Studies Showed STELARA Inhibited the Progression of Structural Damage at Week 24, and Demonstrated Continued Inhibition through Two Years SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA(® )(ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared...

2013-10-28 08:25:51

Budgets are Limiting Wider Prescribing of Biologics; However, Access Will Improve with the Launch of New Drugs and Biosimilars, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis (RA) armamentarium in Argentina and Mexico includes a wide range of premium-priced biologics. However,...

2013-10-28 00:22:31

Hasselt University and INOVA Diagnostics Enter into a Research Collaboration and License Agreement for Novel Diagnostics HASSELT, Belgium and SAN DIEGO, Oct. 28, 2013 /PRNewswire/ -- Hasselt University and INOVA Diagnostics are pleased to announce the completion of an exclusive, worldwide license agreement and research collaboration for technology developed at the University. This technology represents an important advance in the diagnosis of Rheumatoid Arthritis (RA). VIB, the...

2013-10-25 16:23:58

VANCOUVER, Oct. 25, 2013 /PRNewswire/ - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking place at the San Diego Convention Center, October 25-30, 2013. World-leading investigators will present data, including a late-breaking study, describing 14-3-3eta's clinical utility for rheumatoid arthritis (RA)...

2013-10-25 08:24:30

ATLANTA, Oct. 25, 2013 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring multiple data presentations on Cimzia(®) (certolizumab pegol) for the treatment of moderate to severe rheumatoid arthritis and active psoriatic arthritis (PsA) in adults in addition to other oral and poster presentations on investigational data. The data will be presented at the American College of Rheumatology's (ACR) 2013 Annual Scientific...